CA3227713A1 - 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof - Google Patents
8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof Download PDFInfo
- Publication number
- CA3227713A1 CA3227713A1 CA3227713A CA3227713A CA3227713A1 CA 3227713 A1 CA3227713 A1 CA 3227713A1 CA 3227713 A CA3227713 A CA 3227713A CA 3227713 A CA3227713 A CA 3227713A CA 3227713 A1 CA3227713 A1 CA 3227713A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- compound
- alkyl
- cancer
- oxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110860428.3 | 2021-07-27 | ||
| CN202110860428 | 2021-07-27 | ||
| CN202210779302.8 | 2022-07-01 | ||
| CN202210779302 | 2022-07-01 | ||
| PCT/CN2022/107932 WO2023005928A1 (zh) | 2021-07-27 | 2022-07-26 | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227713A1 true CA3227713A1 (en) | 2023-02-02 |
Family
ID=85060847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227713A Pending CA3227713A1 (en) | 2021-07-27 | 2022-07-26 | 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294550A1 (https=) |
| EP (1) | EP4378943A4 (https=) |
| JP (1) | JP2024527044A (https=) |
| KR (1) | KR20240041354A (https=) |
| CN (2) | CN115677730B (https=) |
| AU (1) | AU2022316931A1 (https=) |
| CA (1) | CA3227713A1 (https=) |
| IL (1) | IL310412A (https=) |
| TW (1) | TW202321256A (https=) |
| WO (1) | WO2023005928A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202602891A (zh) * | 2024-03-28 | 2026-01-16 | 大陸商勵締（杭州）醫藥科技有限公司 | 具有mTOR抑制活性的有機化合物及其用途 |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| WO2026037494A1 (en) * | 2024-08-14 | 2026-02-19 | Eracal Therapeutics Ltd. | New compounds and their uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CN109071565B (zh) | 2016-05-24 | 2022-05-10 | 默克专利股份公司 | 三环杂环衍生物 |
| IL281212B2 (en) | 2018-09-07 | 2023-12-01 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use |
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| CN111848605B (zh) | 2019-04-30 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途 |
| CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| JP2023537055A (ja) * | 2020-08-07 | 2023-08-30 | アンテンジーン・ディスカバリー・リミテッド | Ａｔｒ阻害剤およびその使用 |
-
2022
- 2022-07-26 KR KR1020247006386A patent/KR20240041354A/ko active Pending
- 2022-07-26 IL IL310412A patent/IL310412A/en unknown
- 2022-07-26 CN CN202210884665.8A patent/CN115677730B/zh active Active
- 2022-07-26 JP JP2024504951A patent/JP2024527044A/ja active Pending
- 2022-07-26 CA CA3227713A patent/CA3227713A1/en active Pending
- 2022-07-26 TW TW111127974A patent/TW202321256A/zh unknown
- 2022-07-26 AU AU2022316931A patent/AU2022316931A1/en active Pending
- 2022-07-26 WO PCT/CN2022/107932 patent/WO2023005928A1/zh not_active Ceased
- 2022-07-26 CN CN202280052257.4A patent/CN118043325A/zh active Pending
- 2022-07-26 US US18/292,437 patent/US20240294550A1/en active Pending
- 2022-07-26 EP EP22848533.0A patent/EP4378943A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527044A (ja) | 2024-07-19 |
| WO2023005928A1 (zh) | 2023-02-02 |
| EP4378943A1 (en) | 2024-06-05 |
| TW202321256A (zh) | 2023-06-01 |
| EP4378943A4 (en) | 2024-12-11 |
| AU2022316931A1 (en) | 2024-03-14 |
| CN115677730A (zh) | 2023-02-03 |
| US20240294550A1 (en) | 2024-09-05 |
| CN115677730B (zh) | 2024-11-12 |
| KR20240041354A (ko) | 2024-03-29 |
| IL310412A (en) | 2024-03-01 |
| CN118043325A (zh) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112094269B (zh) | 一类饱和六元环并杂环类化合物、制备方法和用途 | |
| US20240270753A1 (en) | Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof | |
| WO2020181283A1 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
| JP2025532125A (ja) | 新規なテトラヘテロサイクル化合物 | |
| AU2014225155B2 (en) | Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof | |
| CA3227713A1 (en) | 8-oxa-3-azabicyclo[3.2.1]octane compounds or salt thereof, and preparation method and use thereof | |
| EP4705281A1 (en) | Compounds for treating cancer | |
| CN115710266A (zh) | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| CN116323562B (zh) | 一类具有激酶抑制活性的化合物 | |
| AU2022345314B2 (en) | Azaindazole macrocyclic compound and use thereof | |
| KR20250048262A (ko) | 아자-퀴나졸린 화합물 및 사용 방법 | |
| US12528799B2 (en) | Heteroaryl derivative compounds, and uses thereof | |
| WO2022253309A1 (zh) | 取代的杂环化合物及其应用 | |
| CN119233974A (zh) | 一种吲哚酮衍生物及其应用 | |
| TW202136267A (zh) | Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑 | |
| CN116375712A (zh) | 双吗啉取代的杂环化合物及其医药用途 | |
| EA050883B1 (ru) | 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение | |
| EP3954680A1 (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | |
| JPWO2023005928A5 (https=) | ||
| WO2024216164A1 (en) | N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer | |
| EP4698531A1 (en) | Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof | |
| CN120731212A (zh) | 作为egfr抑制剂的大环氨基吡啶化合物 | |
| EA052736B1 (ru) | Гетероарильные производные и их применение | |
| HK40064179A (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250721 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250721 |